

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
08/833,838	04/10/1997	BRUCE D. GAYNOR	96700/451	3053
7	7590 01/13/2003			
•	THSTEIN & EBEN	EXAMINER		
90 PARK AVENUE NEW YORK, NY 10016			EWOLDT, GERALD R	
			ART UNIT	PAPER NUMBER
			1644	07
			DATE MAILED: 01/13/2003	21

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary

Application No. 08/833,838

Applicant(s)

Gaynor et al.

Examiner

G.R. Ewoldt

Art Unit **1644**



	The MAILING DATE of this communication appears	on the cover sheet with the correspondence address			
	for Reply				
THE	ORTENED STATUTORY PERIOD FOR REPLY IS SET MAILING DATE OF THIS COMMUNICATION.	TO EXPIRE MONTH(S) FROM no event, however, may a reply be timely filed after SIX (6) MONTHS from the			
mailing	date of this communication.				
- If NO p - Failure - Any re	period for reply specified above is less than thirty (30) days, a reply within the period for reply is specified above, the maximum statutory period will apply a to reply within the set or extended period for reply will, by statute, cause the ply received by the Office later than three months after the mailing date of to patent term adjustment. See 37 CFR 1.704(b).	and will expire SIX (6) MONTHS from the mailing date of this communication. Be application to become ABANDONED (35 U.S.C. § 133).			
Status					
1) 💢	Responsive to communication(s) filed on 9/30/02 a	nd 10/01/02			
2a) 💢	This action is FINAL . 2b) \square This act	ion is non-final.			
3) 🗌	Since this application is in condition for allowance ϵ closed in accordance with the practice under Ex part	except for formal matters, prosecution as to the merits is re Quayle, 1935 C.D. 11; 453 O.G. 213.			
Disposi [,]	tion of Claims				
4) 🗶	Claim(s) <u>54-58 and 71-74</u>	is/are pending in the application.			
4	la) Of the above, claim(s)	is/are withdrawn from consideration.			
5) 🗆	Claim(s)	is/are allowed.			
6) 💢	Claim(s) <u>54-58 and 71-74</u>	is/are rejected.			
7) 🗌	Claim(s)	is/are objected to.			
8) 🗆		are subject to restriction and/or election requirement.			
	tion Papers				
9) 🗆	The specification is objected to by the Examiner.				
10)	The drawing(s) filed on is/are	a) \square accepted or b) \square objected to by the Examiner.			
	Applicant may not request that any objection to the d	rawing(s) be held in abeyance. See 37 CFR 1.85(a).			
11)	The proposed drawing correction filed on	is: a) \square approved b) \square disapproved by the Examiner.			
	If approved, corrected drawings are required in reply t	o this Office action.			
12)	The oath or declaration is objected to by the Exami	ner.			
	under 35 U.S.C. §§ 119 and 120				
_	13) Acknowledgement is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).				
a) _	J All b)□ Some* c)□ None of:				
	1. Certified copies of the priority documents have				
		e been received in Application No			
	3. Copies of the certified copies of the priority do application from the International Bures the attached detailed Office action for a line of the	au (PCT Rule 17.2(a)).			
_	ee the attached detailed Office action for a list of the				
14) ∟ a) □	Acknowledgement is made of a claim for domestic				
	The translation of the foreign language provisiona Acknowledgement is made of a claim for domestic				
Attachm		priority under 35 0.3.C. 33 120 and/or 121.			
	tice of References Cited (PTO-892)	4) Interview Summary (PTO-413) Paper No(s).			
2) No	tice of Draftsperson's Patent Drawing Review (PTO-948)	5) Notice of Informal Patent Application (PTO-152)			
3) 🔲 Infe	3) Information Disclosure Statement(s) (PTO-1449) Paper No(s)				

Serial No. 08/833,838 Art Unit 1644

DETAILED ACTION

- 1. Claims 54-58 and 71-74 are pending.
- 2. Applicant's formal drawings, filed 9/30/02, are acknowledged. The drawings have been found to be acceptable.
- 3. Applicant's amendment and remarks, filed 10/01/02, are acknowledged. In view of Applicant's amendment narrowing the scope of the claims, the previous rejection has been withdrawn in part. Only the rejection under the first paragraph of 35 U.S.C. 112, set forth previously as part B) a method for treating glomerulonephritis mediated by anti-double stranded(ds)-DNA antibodies, remains.
- 4. The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

5. Claims 54-58 and 71-74 stand rejected under 35 U.S.C. 112, first paragraph, because the specification, while being enabling for:

a method for treating glomerulonephritis induced by the administration of the R4A antibody, said treatment comprising the administration of a d-D/E-W-D/E-Y-G/S peptide at the time of the induction of the glomerulonephritis, does not reasonably provide enablement for,

a method for treating glomerulonephritis mediated by antidouble stranded(ds)-DNA antibodies, for the reasons of record as set forth in Paper No. 24, mailed 6/28/02.

Applicant has not traversed this ground of rejection nor has Applicant provided any data supporting the claimed method of treating an established disease.

- 6. No claim is allowed.
- 7. THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of

the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

8. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Dr. Gerald Ewoldt whose telephone number is (703) 308-9805. The examiner can normally be reached Monday through Thursday from 7:00 am to 5:30 pm. A message may be left on the examiner's voice mail service. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Christina Chan can be reached on (703) 308-3973. Any inquiry of a general nature or relating to the status of this application should be directed to the Technology Center 1600 receptionist whose telephone number is (703) 308-0196.

Papers related to this application may be submitted to Technology Center 1600 by facsimile transmission. Papers should be faxed to Technology Center 1600 via the PTO Fax Center located in Crystal Mall 1. The faxing of such papers must conform with the notice published in the Official Gazette, 1096 OG 30 (November 15, 1989). Papers should be faxed to Technology Center 1600 at 703-872-9306 (before final) and 703-872-9307 (after final).

G.R. Ewoldt, Ph.D.
Patent Examiner
Technology Center 1600
December 27, 2002

Patrick J. Nolan, Ph.D. Primary Examiner Technology Center 1600